OM-85 for Childhood Eczema: Fewer Repeated Flares Did Not Mean Most Children Stayed Flare-Free
DOCTOR’S NOTES · ECZEMA EVIDENCE
A study can report fewer repeated eczema flares while most children in both groups still experience at least one flare. OM-85 research illustrates why a hazard ratio should not be rewritten as the percentage of children whose eczema disappeared.
An add-on trial in young children
Bodemer and colleagues’ 2017 randomized double-blind study enrolled children aged six months to seven years with established atopic dermatitis. OM-85, a standardized oral bacterial lysate, or placebo was added for nine months to emollients and topical corticosteroids. Of 179 randomized children, 170 were analyzed: 88 active and 82 placebo.
| Outcome | OM-85 | Placebo |
|---|---|---|
| Children with at least one new flare | 75/88, about 85% | 72/82, about 88% |
| Primary repeated-flare analysis | Hazard ratio 0.80 | 95% confidence interval 0.67–0.96 |
The adjusted repeated-flare estimate was 0.82, 95% confidence interval 0.69–0.98. The analysis accounted for recurring events; its interpretation is different from simply comparing whether a child ever flared.
Why “20% fewer children” would be misleading
A hazard ratio of 0.80 describes the modeled relative rate over time for the specified recurring-event outcome. It does not say that 20 percentage points fewer children had a flare, that every child had 20% fewer flares or that 20% were cured. The displayed any-flare proportions make that distinction concrete.
For a family, recurrence, time between flares and total burden may all matter. Those are worthwhile outcomes, but they need their own definitions. A study result becomes less useful when a headline changes the question from frequency over time to complete prevention.
Keep background care and sponsorship visible
Both groups continued conventional eczema treatment. The result therefore concerns an adjunct, not a replacement for moisturizers or prescribed anti-inflammatory care. The paper discloses manufacturer-employee authors and a relevant manufacturer role in design, data, analysis and publication. That does not erase the result; it is information readers should have when assessing it.
The term bacterial lysate also should not be translated into a claim that any probiotic, fermented food or deliberate infection will produce the same effect. Preparation and route are part of the intervention. A hypothesis about microbial exposure is not a home treatment protocol.
How to use this evidence in a care conversation
Ask the clinician how flares are defined in your child’s plan, when a recurrence should trigger review and what practical outcome an additional intervention is expected to improve. Keep a short account of episodes and treatments used rather than relying on memory of the worst week alone.
The AAD guideline hub provides the broader clinical context. This research regimen is not an instruction to obtain OM-85 independently or to assume availability or authorization in a particular country.
Why a broad “immune boosting” explanation needs condition-specific clinical evidence
Where moisture care fits
Dr. Arsy Moisturizer #003, 4 oz (120 g) is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. It does not treat, cure or prevent eczema and was not tested in the research discussed here. These findings do not establish pediatric efficacy or infant suitability for #003; ask a child’s clinician about an appropriate moisturizer.
Continue with a related question
- How to Read an Eczema Study Without Getting Misled by Percentages
- Your Eczema Itch Score and Your Rash Score Can Tell Different Stories
- What Is SCORAD? Understanding an Eczema Severity Score
Prepared by the Dr. Arsy editorial team. Sources checked November 9, 2026. Educational content does not diagnose an individual or imply independent medical review. Cited researchers and institutions do not endorse #003. Image is an AI-created editorial product illustration, not a patient photograph or clinical result.